By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


RedHill Biopharma Ltd. 

21 Ha’arba’a Street

Tel-Aviv    64739  Israel
Phone: 972-0-3-541-3131 Fax: 972-0-3-541-3144



Company News
RedHill Biopharma (RDHL) Announces Enrollment Of Last Patient In BEKINDA Phase III Study For Acute Gastroenteritis 2/13/2017 12:03:01 PM
RedHill Biopharma (RDHL) Release: Pharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections 1/11/2017 8:22:01 AM
RedHill Biopharma (RDHL) Release: Pharma Announces First Dosing In RHB-105 Supportive PK Studies Ahead Of Confirmatory Phase III Study For H. Pylori Infection 1/10/2017 11:01:47 AM
RedHill Biopharma (RDHL) Announces YELIVA (ABC294640) Abstract Presentation At The 2017 Cholangiocarcinoma Foundation Annual Conference 1/6/2017 10:13:03 AM
RedHill Biopharma (RDHL) Announces Exclusive U.S. Co-Promotion Agreement With Concordia (CXR.TO) For GI Drug Donnatal 1/3/2017 8:57:57 AM
RedHill Biopharma (RDHL) Announces First Patient Dosed In Phase Ib/II Study With YELIV For Multiple Myeloma 12/19/2016 8:15:30 AM
RedHill Biopharma (RDHL) And IntelGenx Corp. Announce Definitive Agreement For Commercialization Of Rizaport For Migraines With Pharmatronic Co. In South Korea 12/14/2016 9:34:17 AM
RedHill Biopharma (RDHL) Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease 12/13/2016 10:12:32 AM
RedHill Biopharma (RDHL) Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis 12/12/2016 8:56:58 AM
RedHill Biopharma (RDHL) Announces YELIVA (ABC294640) Poster Presentation At The 2016 EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium 11/21/2016 11:20:10 AM